Dronedarone-induced digoxin toxicity: new drug, new interactions
Ajay Vallakati1, Preeti A Chandra, Manali Pednekar
1Department of Medicine, Maimonides Medical Center, Brooklyn, NY.
American Journal of Therapeutics
|April 27, 2011
Summary
Dronedarone significantly raises digoxin levels, increasing the risk of toxicity. Careful monitoring or dose adjustment of digoxin is crucial when co-administered with dronedarone.
Area of Science:
- Pharmacology
- Cardiology
- Drug Interactions
Background:
- Dronedarone is an antiarrhythmic medication used for atrial fibrillation.
- Digoxin is a cardiac glycoside used to treat heart failure and arrhythmias.
- P-glycoprotein plays a role in the elimination of various drugs, including digoxin.
Observation:
- Dronedarone inhibits P-glycoprotein, a transporter protein.
- This inhibition reduces the clearance of digoxin from the body.
- Concomitant use of dronedarone and digoxin can lead to a 2.5-fold increase in steady-state digoxin levels.
Findings:
- A case of digoxin toxicity was observed in a patient receiving both dronedarone and digoxin.
- The toxicity resulted from the drug-drug interaction between dronedarone and digoxin.
- Elevated plasma digoxin levels were confirmed, correlating with the observed toxicity.
Implications:
- Close monitoring of plasma digoxin levels is essential in patients taking both medications.
- Consideration should be given to reducing the loading dose of digoxin when initiating dronedarone.
- This interaction highlights the importance of pharmacovigilance for antiarrhythmic drug combinations.
Related Concept Videos
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...